I

t’s been a good month for companies developing the experimental immunotherapies known as CAR-T, as several released data showing strong results in patients with blood cancers.  Now, though, they face a new challenge: Proving they can actually manufacture the highly personalized treatments quickly and efficiently — and get them to cancer patients across the country. 

And hidden in some of the positive data are hints that such turnarounds will be tough.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.